Close
Close

Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders

Descriptive Information
Brief Title † Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders
Official Title † Open, Prospective, Uncontrolled, Multicentre Study to Evaluate The Safety and Efficacy of Multiple Applications of Liver Cell Suspension Into The Portal Vein in Children With Urea Cycle Disorders (UCDs)
Brief Summary Urea cycle disorders are rare inherited diseases that generally have a poor outcome. In this study, neonates and infants with UCD will be included within the first 3 months of life and will be treated by repetitive application of human liver cells to reduce the risk of neurological deterioration while awaiting OLT.
Detailed Description Urea cycle disorders are rare inherited diseases that generally have a poor outcome, especially with onset of the disease in the neonatal period. UCDs are caused by a deficiency of one of six enzymes responsible for removing ammonia from the bloodstream. Instead of being converted into urea which is removed from the body with the urine, ammonia accumulates in UCD patients leading to brain damage or death. In the light of a mortality rate of > 50% at the age of 10 years the current pharmacological and dietary therapy is of modest success. Furthermore, mental retardation, cerebral palsy and other neurological sequelae are common among surviving patients. In the last years, orthotopic liver transplantation (OLT) has become the best therapeutic option for UCD with long-term survival rates of about 90%. However, in the first weeks of life OLT still is technically demanding and prone to complications. With larger size of the recipient, the technical problems with OLT decrease considerably. The increased body weight usually achieved at the age of more than 8 weeks is related to a major reduction in transplantation related morbidity. Stabilization of metabolism until the patient can undergo OLT is essential. In this study, neonates and infants with UCD will be included within the first 3 months of life and will be treated by repetitive application of human liver cells. In the last consequence, the aim of this new therapy option is to supply a sufficient amount of healthy liver cells to compensate for the metabolic defect and to reduce the risk of neurological deterioration while awaiting OLT.
Study Phase Phase 2
Study Type † Interventional
Study Design † Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary Outcome Measure † Safety of the application of liver cells, safety of the placement of an application catheter to the portal vein.
Secondary Outcome Measure † Changes in 13C urea formation. Changes in the respective enzyme activity in liver biopsies from the explanted organ compared to the enzyme activity in the liver before cell application.
Condition † Urea Cycle Disorders Carbamoylphosphate Synthetase I Deficiency Ornithine Transcarbamylase Deficiency Citrullinemia
Intervention † BiologicalHuman Heterologous Liver Cells
Study Arms / Comparison Groups
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status † Biological
Estimated Enrollment † 15
Start Date † July 2008
Completion Date December 2015
Primary Completion Date December 2015
Eligibility Criteria † Inclusion Criteria - Neonates and infants up to the age of ≤ 3 months with prenatally or postnatally confirmed urea cycle disorder and - Children aged > 3 months up to ≤ 5 years of age with unstable metabolism and confirmed urea cycle disorder of either: - Carbamylphosphate synthetase I [CPSD] or - Ornithine transcarbamylase [OTCD] or - Argininosuccinate synthetase [Citrullinaemia] - A DNA analysis will further confirm diagnosis prior to or after inclusion according to the protocol. - Accessibility of the portal vein - Plasma ammonia level ≤ 250 μmol/l - Written informed consent Exclusion Criteria - Structural liver disease (cirrhosis, portal hypertension), or venoocclusive diseases - Portal vein thrombosis - Body Weight ≤3.5 kg - Carrier of the human immuno-deficiency virus (HIV) - Any other contraindication for immunosuppression - Presence of acute infection at the time of inclusion - Participation in other clinical trials or received experimental medication within the last 30 days - Live vaccination planned during the course of the study - Live vaccination within 4 weeks prior to beginning of study - Allergic disposition against contrast medium used in study and/or antibiotics used in the manufacturing process - Required valproate therapy - Severe coagulopathy or thrombocytopenia - Known diagnosis of hereditary thrombophilia (e.g. Factor V Leiden, Prothrombin 20210A variant) or parental history of hereditary thrombophilia and absense of thrombophilia testing in subject - Cancer, severe systemic or chronic disease other than study indication (urea cycle deficiency)
Gender Both
Ages N/A - 5 Years
Accepts Healthy Volunteers No
Contacts ††
Location Countries † Germany
Administrative Information
NCT ID † NCT00718627
Organization ID CCD02
Secondary IDs †† CCD02, 2006-000136-27
Responsible Party Sponsor
Study Sponsor † Cytonet GmbH & Co. KG
Collaborators ††
Investigators † Principal Investigator: Georg F. Hoffmann, MD, University Children's Hospital, Heidelberg
Information Provided By
Verification Date December 2014
First Received Date † July 16, 2008
Last Updated Date December 9, 2014
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Related Videos
by Abidemi Uruejoma
260 views
by Abidemi Uruejoma
6,801 views
Free Newsletter